Australia's Imricor Medical Systems rises on John Hopkins clinical trial approval
18/01/2024 03:19
** Shares of Imricor Medical Systems IMR.AX rise as much
as 7.4% to A$0.565, their biggest intraday pct gain since Jan.
11
** Medical devices developer says Johns Hopkins Hospital’s
Institutional Review Board has approved commencement of the
VISABL-AFL clinical trial
** Adds VISABL-AFL is the clinical trial supporting US FDA
approval of co's products
** Stock rose 56.2% last year
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion